Raysearch Laboratories
219.80 SEK
+3.48 %
Less than 1K followers
RAY B
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data
Income statement
Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for Raysearch Laboratories
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | 741.6 | 651.6 | 641.1 | 843.7 | 1,022.2 | 1,192.0 | 1,344.3 |
| growth-% | -12.1 % | -1.6 % | 31.6 % | 21.2 % | 16.6 % | 12.8 % | |
| EBITDA | 250.7 | 209.8 | 196.7 | 339.7 | 400.1 | 558.0 | 583.6 |
| EBIT | 68.2 | -3.5 | -53.5 | 42.7 | 114.9 | 260.5 | 292.3 |
| Profit before taxes | 62.6 | -6.5 | -58.9 | 32.4 | 110.1 | 262.9 | 287.8 |
| Net income | 50.4 | -9.1 | -47.3 | 23.8 | 81.6 | 203.5 | 227.8 |
| EPS | 1.47 | -0.26 | -1.38 | 0.69 | 2.38 | 5.94 | 6.65 |
| Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 2.00 | 3.00 | 4.00 |
| Dividend ratio | 0.0 % | -0.0 % | -0.0 % | 0.0 % | 84.0 % | 50.5 % | 60.2 % |
Profitability and return on capital
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| EBITDA-% | 33.8 % | 32.2 % | 30.7 % | 40.3 % | 39.1 % | 46.8 % | 43.4 % |
| EBIT-% | 9.2 % | -0.5 % | -8.3 % | 5.1 % | 11.2 % | 21.9 % | 21.7 % |
| ROE | 7.1 % | -1.3 % | -7.3 % | 3.6 % | 11.1 % | 23.2 % | 23.1 % |
| ROI | 4.0 % | -0.7 % | -2.7 % | 1.3 % | 4.2 % | 9.7 % | 11.4 % |